Renal Dosing Master release notes

1,036 records. All 987 v7.2 records remain available. This release adds 49 product records and expands 41 existing records. Each of the 90 products has a GlobalRPh RX summary and a separately attributed product-label summary. Thirteen additional summaries cover guidance from UCSF, the HHS HIV guidelines panel, eviQ, Cancer Care Ontario and BC Cancer.

Browse the 90 clinical updates Review source cautions

What changed for clinicians

Filter for a dose change, restriction, qualified no-adjustment instruction, monitoring requirement or evidence gap. The drug, formulation and renal measure stay with the answer. In the medication-list tool, a bare tirzepatide entry now offers both Mounjaro and Zepbound for confirmation.

For selected high-risk regimens, labeled tables distinguish route, indication, infusion time and dialysis timing. Institutional regimens appear in their own evidence cards. The atenolol mirror with an IV heading and oral instructions is held for editorial review.

Coverage and remaining review

839 of 4,442 indexed RX URLs contain selected content (18.89%). There are 3,602 confirmed URLs without selected renal content, 666 unresolved listed destinations and one candidate URL. Full protocol completion has no validated denominator.

The external search screened 100 discovered domains and separately rechecked the inherited 100 reference URLs. Direct Google ranks were unavailable. The two lists may overlap.

Independent clinician approval is pending. Some selected labels are dated and carry a currency caution. Source summaries do not establish independent corroboration when they derive from the same label.